Tele: 561.316.3330
Breaking Medical Device News

Tuesday, September 21, 2021


HomeNeoTractNeoTract Inc. Announces Presentations of Multiple Clinical Studies Featuring Five-Year Data from Pivotal Randomized Trial of UroLift®

NeoTract Inc. Announces Presentations of Multiple Clinical Studies Featuring Five-Year Data from Pivotal Randomized Trial of UroLift®

Announced at the American Urological Association 2017 Meeting

NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, today announced activities planned for the 112th American Urological Association Annual Meeting taking place May 12-16 at the Boston Convention and Exhibition Center in Boston, Mass.

The company’s events and activities will highlight the UroLift® System, a revolutionary minimally invasive approach to treating benign prostatic hyperplasia (BPH), also called enlarged prostate. These presentations include:

  • Friday, May 12, 7:00 am ET in Room 156, poster presentation by Dr. Karl-Dietrich Sievert: Minimally Invasive Prostatic Urethral Lift (PUL) Efficacious in a Large Percentage of TURP Candidates: A Multi-Center German Study After Two Years
  • Saturday, May 13, 7:00am-9am ET in Room 252: presentations of results from the Crossover Study (Prof. Henry Woo); the LOCAL Study (Dr. Steven Gange); and Commercial Use (Dr. Andrew Hirsh)
  • Saturday, May 13, at 1:00pm ET in Room 162: Five-year results from the pivotal L.I.F.T. randomized study presented by Dr. Claus Roehrborn as part of a podium session titled BPH: Surgical Therapy & New Technology IV
  • Sunday, May 14, 9:30-10:30am ET, in the Plenary Room: A presentation of Prime Time Surgical Techniques featuring the UroLift System, including a presentation and case demonstration of the UroLift System by Dr. Shahin Tabatabei
Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

FDA Authorizes Software that Can Help Identify Prostate Cancer

The software is called Paige Prostate and is compatible for use with slide images that have been digitized using a scanner.

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

By using this website you agree to accept Medical Device News Magazine Privacy Policy